Other

https://doi.org/10.20471/sept.2024.60.03.09

Dexmedetomidine

Vjekoslav Peitl orcid.org/0000-0003-4163-6411 ; Department of Psychiatry, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; School of Medicine, Catholic University of Croatia, Zagreb, Croatia *
Darko Vlahović ; Department of Psychiatry, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia

* Corresponding author.

Abstract

Recent research highlights the potential of dexmedetomidine, an α2-adrenoreceptor agonist, as a preventive treatment for postpartum depression (PPD). Originally studied in anesthetic settings, dexmedetomidine has shown antidepressant effects, reducing agitation and depressive symptoms. It is sedative, anxiolytic, and analgesic, targeting α2-adrenoreceptors implicated in depression. Studies link increased α2-adrenoreceptor activity and reduced brain-derived neurotrophic factor (BDNF) levels to PPD. Dexmedetomidine appears to modulate these pathways, promoting neuroplasticity and mood regulation.

Keywords

Dexmedetomidine

Hrčak ID:

323293

URI

https://hrcak.srce.hr/323293

Publication date:

1.12.2024.

Visits: 864 *